NurExone Biologic Inc. reports financial results for Q1 2024 with net loss of $0.92 million.

From GlobeNewswire: 2024-05-29 08:35:00

NurExone Biologic Inc. releases financial results for Q1 of 2024. Key highlights include initiating in-house labs, accelerating warrants, securing OTCQB Venture Market approval, and FDA approval for animal testing of ExoPTEN drug. CEO Dr. Shaltiel emphasizes commitment to regenerative medicine transformations and collaboration with Teva Pharmaceutical VP Dr. Petter. Financial results show decreased R&D expenses but increased G&A expenses, resulting in a net loss of $0.92 million for Q1. The Company maintains a strong cash position for continued growth and success.



Read more at GlobeNewswire:: NurExone Reports First Quarter 2024 Financial Results and